Latest News and Press Releases
Want to stay updated on the latest news?
-
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian...
-
Wilmington, Delaware, United States, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global automatic swimming pool monitoring system market is projected to flourish at a...